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AsthmaMaterials and methods: One hundred and nineteen smoking, non-smoking and ex-smoking
patients (25e65 yrs) with asthma, COPD or both, were recruited by 33 GPs and 33 specialists.
Data were obtained retrospectively from medical records. However, only a small number of
files were complete.
Results: The majority of COPD patients were (ex-)smokers: 94% in the specialist group, 78%
in the GP group. Cardiovascular comorbidity appeared in both groups in the same frequency
order: COPD> (ex-)smoking patients with asthma (AS)> non-smoking patients with asthma
(ANS), with a significant difference between AS and ANS in the specialist population. Chronic
cough during more than 3 months in two consecutive years was reported in 97% of COPD
patients, in 71% of the AS patients and in only 25% of the ANS patients. The type of cough
differed between AS and ANS in the GP group, with a higher prevalence of productive cough
in the former. Treatment patterns observed were as expected according to diagnosis except
for a disproportionate use of Tiotropium in AS in the GP group.
Conclusion: ASwere somewhere in betweenCOPDpatients andANS for a large numberof the char-
acteristics studied, suggesting that theyarean intermediatephenotypebetweenCOPDandasthma.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
In Belgium, the prevalence of active smoking varies
between 24% and 28%.1 It is well known that the inhalation
of tobacco smoke is harmful to the airways: lung cancer,
chronic obstructive pulmonary disease (COPD) and asthma
are diseases that are clearly linked to the consumption of
tobacco.2e4 Smoking is associated with an increase in
inflammatory cells, increased concentrations of cytokines
and structural changes in the bronchial biopsies.1,5,6
Smoking is also very common among adults suffering from
asthma and tends to mirror the rates found in the general
Belgian population.7 Recently, several studies have been
published describing the harmful influence and important
interactions of cigarette smoking on asthma.8e10 Smokers
with asthma appear to have more frequent and more severe
asthma symptoms, are less likely to have well-controlled
asthma, and showagreater health careuse compared tonon-
smoking asthma patients. Smoking alters the natural history
of asthma by a modified inflammatory pattern with higher
airway and sputum neutrophil counts, an accelerated lung
function decline and a more important risk of developing
persistent airflow obstruction. Those features may make it
difficult to differentiate asthma fromCOPD, especially in the
knowledge that approximately 10e20% of the patients with
obstructive lung disease show characteristics of both asthma
and COPD. Finally, asthma medications such as inhaled
corticosteroids have been found to be less effective in
smoking asthma patients compared to non-smoking asthma
patients.1,11,12 Those findings are also accepted by and
described in the GINA (global initiative for asthma) andGOLD
(global initiative for chronic obstructive lung disease)
guidelines for asthma and COPD. The GINA guidelines
conclude that smokers are less likely to achieve control and
remain at risk of exacerbations.
One of the major problems in the treatment of smoking
asthma patients is the lack of efficacy data in this group of
patients as smokers have almost always been excluded
from studies on asthma due to perceived concerns about
recruiting patients with COPD. Instead, we have performed
a survey with the aim to determine the prevalence, the
characteristics, and the management approach of this veryheterogeneous and poorly studied patient population
within the Belgian practice, both at the level of the
specialist and of the general practitioner (GP).
Materials and methods
This study was conducted by means of diaries in order to
collect objective and measurable data (e.g. results from
diagnostic tests) contained in medical records from
patients suffering from obstructive lung disease. In order to
be included, patients had to be between 25 and 65 years
old for COPD patients and between 12 and 65 years for
asthma patients, and treated with at least one of the
following drugs: short-acting bronchodilators (SABA, anti-
cholinergics), long-acting bronchodilators (LABA, anticho-
linergics), inhaled or oral corticosteroids, antileukotrienes,
or a fixed combination of these drugs.
The study ran from January to May 2007. Both GPs and
specialists (33 in each group) spread over the country
participated in the study. Data were collected in a retro-
spective manner and were obtained from 191 medical
records (Table 1). Patient recruitment was prospective with
inclusion of the patient file of the first three successive
patients seen during consultation or home visit and
responding to the inclusion criteria. A patient file was taken
into account for analysis as soon as one of the following
diagnoses was given by the GP or specialist involved:
asthma, COPD or both (mixed diagnosis). However, only
a small number of files were complete, which is reflected in
the varying numbers in the results section of this publica-
tion. In case of a mixed diagnosis, the patient file was
included in the asthma group for analysis. Smoking and ex-
smoking asthma patients were included in the smoking
asthma patient group. All specialist medical records taken
into account for analysis were examined for correlation on
the given diagnosis and the results of the diagnostic tests. If
these did not match, the patient files were submitted to
two independent experts. If they agreed to the same
diagnosis, this diagnosis was considered to be correct and
final; if not, the diagnosis was considered to be ambiguous
and the patient files were included in the analysis according
to the initial diagnosis.
Table 1 Division of medical records collected by GPs, specialists and total.
GPs (base nZ 33) Specialists (base nZ 33) Total GPsþ Specialists
(base nZ 66)
Number of patient files 100 91 191
Non-smoking asthma patients 40 (40%) 29 (32%) 69 (36%)
(Ex-)smoking asthma patientsa 23 (23%) 15 (16%) 38 (20%)
COPD only 37 (37%) 47 (52%) 84 (44%)
a All patients suffering from asthma; patients with a ‘mixed’ diagnosis are included.
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In order to evaluate the characteristics and management
approach of smoking asthma patients, chi-square testing
was applied, with 95% confidence intervals, between this
patient group and the 2 other control groups (non-smoking
asthma patients and patients with COPD). The difference
was considered statistically significant at p< 0.05. In order
to detect tendencies and possible differences between
groups, also p-values <0.1 were retained.
Results
Patient characteristics
At the level of the specialist, 91 patient files were included
in this survey. The characteristics of these patients are
shown in Table 2. The large majority (44/47, 94%) of the
COPD patients were (ex-)smokers. Age at diagnosis was
comparable in both the (ex-)smoking asthma patients group
(AS) and the non-smoking asthma patients group (ANS). The
age at diagnosis in the COPD group was statistically
different from that in both asthma groups. Prevalence of
atopic conditions such as allergic rhinitis and atopic eczemaTable 2 Patient characteristics.
Characteristic Specialists
ANS AS
n (%) 29 (32%) 15 (17%)
Agea
<40 15 (52%) 4 (27%)
>40 14 (48%) 11 (73%)
Gender
_ 8 (28%) 6 (40%)
\ 21 (72%) 9 (60%)
Age at diagnosisa,c
<40 17 (71%) 6 (50%)
>40 7 (29%) 6 (50%)
Atopic conditionsa,c 92% (23/25) 77% (10/13)
Cardiovascular comorbidityb 3% (1/29) 27% (4/15)
a p< 0.05 AS vs. COPD (both populations).
b p< 0.05 AS vs. ANS (specialist population).
c p< 0.05 AS vs. ANS (GP population).was comparable in both groups of asthma patients (77% and
92% in the AS and ANS group, respectively) and was signif-
icantly different between the AS group and the COPD group
(7%). For cardiovascular co-morbidities, a statistically
significant difference was noted between the AS and ANS
group (27% versus 3%, respectively). The number of
ambiguous diagnoses was the highest in the AS group (4/15,
27%) compared with (2/29, 7%) the ANS and the COPD group
(7/47, 15%).
A total of 100 appraisable patient files was obtained
from 33 GPs. The characteristics of this population are
given in Table 2. In the COPD group, 75% (29/37) of the
patients were smokers/ex-smokers. Diagnosis was made
mainly above the age of 40 (86%) in COPD patients, and
below the age of 40 (85%) in the ANS group. In the AS group,
diagnosis seemed to be made at an intermediary age. The
difference between the AS and both other groups was
statistically significant (p< 0.05 for AS versus ANS and
versus COPD). A relatively high percentage of COPD
patients with atopic conditions was noted (25%). The
prevalence of atopic conditions in the AS was intermediary
too and was statistically significantly different from the
prevalence found in both other groups (p< 0.05 for AS
versus ANS and versus COPD). Although not statistically
significant, cardiovascular comorbidity appeared in theGPs
COPD ANS AS COPD
47 (52%) 40 (40%) 23 (23%) 37 (37%)
1 (2%) 13 (32%) 6 (26%) 0 (0%)
46 (98%) 27 (68%) 17 (74%) 37 (100%)
30 (64%) 19 (48%) 14 (61%) 23 (62%)
17 (36%) 21 (52%) 9 (39%) 14 (38%)
1 (2%) 34 (85%) 12 (53%) 5 (14%)
40 (98%) 6 (15%) 11 (47%) 32 (86%)
7% (3/44) 92% (34/37) 68% (13/19) 25% (8/32)
43% (20/47) 23% (6/26) 33% (3/9) 52% (14/27)
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COPD> AS> ANS.Symptoms
Symptomatic characteristics of the three patient groups
observed at the level of the specialists are described in
Table 3. Cough outside exacerbations was present in 68%,
53% and 28% of the COPD, AS and ANS patients, respec-
tively. For dyspnoea outside periods of exacerbations, the
AS group was similar to the COPD group (73% and 83%,
respectively) whereas a statistically significant difference
was observed with the ANS group (24%) (p< 0.05).
However, cough remained dry in both asthma groups
(62% and 75% for the AS and ANS groups, respectively),
whereas it had a productive character in 81% of the COPD
patients (p< 0.05). Chronic cough during more than 3
months in 2 consecutive years was reported in 97% of COPD
patients, in 71% of the AS patients and in only 25% of the
ANS patients. For this symptom, the results obtained in the
AS group differed significantly from those of the COPD
group (p< 0.05). Nighttime/morning dyspnoea was more
often reported in both asthmatic patient groups compared
to COPD patients (AS versus COPD, p< 0.05). In general,
presence of wheezing outside periods of exacerbations was
rarely reported as a symptom. Common cold seemed to be
more often associated with bronchitis in both the AS and
the COPD groups compared to the ANS group (p< 0.1).
Additionally, a tendency for more frequent hospitalizations
for respiratory problems existed in the COPD and the AS
group compared to the ANS group (p< 0.1). For all other
symptoms, no statistically significant differences between
the groups were observed.
Table 3 gives an overview of the symptoms observed in the
patients of the GP population. Similar to the observations
performed in the specialist population, the patients of the AS
group showed more frequent cough (70%) and dyspnoea
(78%) outside periods of exacerbations compared to what
was seen in the ANS group (44% for both symptoms)
(p< 0.05). Although not statistically significant, wheezing
was also reported more often in the AS (56%) compared to
both other groups (44% and 40% in the ANS and COPD group,
respectively). Coughwasmostly productive in COPD patients
(79%), whereas it was predominantly dry in ANS patients
(88%). In the AS group, cough seemed to be dry or productive
at equal frequencies. Regarding type of cough, the patients
of the AS group differed from theANS patients (p< 0.05), but
also tended to be different compared to the COPD patients
(p< 0.1). Chronic cough during more than 3 months of 2
consecutive yearswas present in 92%of theCOPDpatients, in
88% of the AS, and in 69% of the ANS. These percentages were
remarkably high for the asthmatic groups, especially for the
non-smoking patients. Although not examined for signifi-
cance, nighttime dyspnoea seemed to be reported less
frequently by asthmatic patients and more often by COPD
patients compared to what was seen at specialist level.
Regarding common cold with bronchitis, a similar trend was
seen for general practitioner patients as for specialist
patients, with the presence of this symptom mainly in the
COPD and AS, but the differences between the AS group and
both other groups were not statistically significant.Hospitalization for respiratory problems occurred in 47%,
48% and 22% of the COPD, AS and ANS patients, respectively.
The trend was similar as for the specialist population with
a significant difference between the AS and the ANS group
(p< 0.05). Aggravation of dyspnoea over the last years was
noticed in a similar percentage of COPD patients and AS
patients and in a lower percentage in the ANS (p< 0.05
versus ANS). For all other evaluated symptoms, the differ-
ences between the groups were not significant and the
number of appraisable patients was too low to draw valuable
conclusions.
At the level of the specialists, statistically significant
differences in the age of patients (p< 0.05) could only be
observed for wheezing (AS group) and hospitalization (ANS
group). At the level of the GPs, statistically significant
differences in the age of patients (p< 0.05) were observed
for cough (ANS and COPD groups), and for dyspnoea, cold
and hospitalization (AS group). No statistically significant
gender differences (p< 0.05) could be observed.Diagnostic tests
Spirometry
Baseline pre-bronchodilator FEV1/FVC was <70% in 90%,
62% and 52% of the COPD, AS and ANS patients, respec-
tively. A statistically significant difference was observed
between the AS and COPD group (p< 0.05).
Table 4 shows the distribution over the different GOLD
stages of the post-bronchodilator FEV1 values (collected in
the specialist group only), expressed as a percentage of the
predicted values. In total, 84% of the COPD patients were
GOLD stage II and III (42% each). In the AS group, 54% had
FEV1 values corresponding to GOLD stage II; in the ANS
group, FEV1 values were 80% of the predicted values
(GOLD stage I) in 65% of the patients. The overall distri-
bution over the different GOLD stages was statistically
significantly different between the AS group and the COPD
group (p< 0.05).
Reversibility expressed as a percentage (of the pre-
dicted or baseline value all together) was inferior to 12% in
84% of the COPD patients compared with 54% in the AS
group and 52% in the ANS group. No statistically significant
differences between the groups could be observed.
Reversibility testing based on the difference in absolute
value post-bronchodilation was negative (<200 mL) in 75%
of the COPD patients. In both asthma patient groups
approximately 25% of these tests were negative (27% and
25% for ANS and AS, respectively). The difference between
the AS and the COPD patients was statistically significant
(p< 0.05).
Peak flow data were available for 40% (19/47) of the
COPD patients, 47% (7/15) of the (ex-) smoking asthma
patients and for 41% (12/29) of the patients in the ANS. The
distribution of the patients over the different ranges of
percentages of predicted PEF values showed no statistically
significant differences between the AS and the two other
groups.
At the level of the GPs, only a limited number of data was
available for the spirometry tests. Tiffeneau results on
pre-bronchodilationwere available for only 32% (12/37), 22%
(5/23) and 20% (8/40) of the COPD, AS and ANS patients,
Table 3 Symptomatic characteristics of all patient groups.
Symptom Specialists GPs
ANS (%) AS (%) COPD (%) ANS (%) AS (%) COPD (%)
Cougha, d,f 28 53 68 44 70 68
Typeb, e, f
Productive 25 38 81 12 53 79
Dry 75 62 19 88 47 21
3 months in 2 consecutive yearsb,d 25 71 97 69 88 92
Induced by fresh air 88 50 38 81 64 86
Induced by effort 75 43 35 82 67 67
Age difference NS NS NS p< 0.05 NS p< 0.05
Gender difference NS NS NS NS NS NS
Dyspnoeaa, c, d 24 73 83 44 78 83
Continuous 0 30 55 25 17 33
Intermittent 100 70 45 75 83 67
Present at rest
Rarely 100 67 50 38 56 55
Sometimes 100 83 34 56 39 34
Oftene,g 0 17 16 6 6 10
Induced by effort
Duringb 57 90 92 69 88 56
After 14 10 5 25 0 15
During and after 29 0 3 6 12 30
Awaking at night/morningg 71 46 14 53 33 34
More severe during last years 71 73 74 20 61 63
Age difference NS NS NS NS p< 0.05 NS
Gender difference NS NS NS NS NS NS
Wheezinga 21 33 30 44 56 40
Continuous 0 25 36 13 8 29
Intermittent 100 75 64 87 92 71
Present at rest
Rarely 60 50 21 67 62 46
Sometimes 40 50 43 33 31 31
Often 0 0 367 0 8 23
Induced by effort
During 80 67 73 64 91 54
After 20 0 9 36 9 27
During and after 0 33 18 0 0 18
Awaking at night/morning 33 40 31 40 40 36
Age difference NS p< 0.05 NS NS NS NS
Gender difference NS NS NS NS NS NS
Cold (often associated with symptoms of bronchitis)d 67 93 90 70 86 86
Age difference NS NS NS NS p< 0.05 NS
Gender difference NS NS NS NS NS NS
Hospitalization for respiratory problemsd,f 32 60 49 22 48 47
Age difference p< 0.05 NS NS NS p< 0.05 NS
Gender difference NS NS NS NS NS NS
NS: not significant.
a Presence of symptom outside exacerbations period.
b p< 0.05 AS vs. COPD (specialist population).
c p< 0.05 AS vs. ANS (specialist population).
d p< 0.1 AS vs. ANS (specialist population).
e p< 0.1 AS vs. COPD (GP population).
f p< 0.05 AS vs. ANS (GP population).
g p< 0.1 AS vs. ANS (GP population).
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Table 4 Distribution of patients over GOLD stages.
Distribution of FEV1 over GOLD
stagesa
ANS (%) AS (%) COPD (%)
80% (I) 65 36 7
50 to <80% (II) 26 54 42
50 to <60% 9 9 13
60 to <80% 17 46 29
30 to <50% (III) 9 0 42
<30% (IV) 0 9 10
a p< 0.05 AS vs. COPD for overall distribution over different GOLD stages.
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<70% in 83%, 60% and 25% of the COPD, AS and ANS patients,
respectively. Data concerning the repartition of the post-
bronchodilator FEV1 values based on GOLD guidelines were
available only for 24% (9/37) of theCOPDpatients, 26% (6/23)
of the AS patients, and for 20% (8/40) of the ANS patients.
Other tests
In the specialist population, diffusion capacity was
decreased in 78% (32/41) of the COPD patients, whereas
this was observed in only 38% (5/13) and in 9% (2/22) of the
AS and ANS patients, respectively (p< 0.05 AS vs. COPD).
Specific IgE testing results were positive for at least one
allergen in 11% (3/28) of the COPD patients, and in 54% (7/
13) and 53% (9/17) of the patients in the AS group and the
ANS group, respectively. Prick tests were positive for at
least 1 allergen in 40% (4/10) of the COPD patients, in 71%
(5/7) of the AS and in 94% (15/16) of the ANS patients.
At the level of the GPs, data on diffusion capacity were
only available for 14% of the COPD patients and also for
a minority of the patients in both other groups. As for the
specialists, general practitioners rarely saw positive allergy
tests in the COPD patients. Specific IgE testing results were
available and positive for at least 1 allergen in 12% (4/32) of
the cases in the COPD group, for 32% (6/19) in the AS and for
50% (17/34) in the ANS. Prick tests were positive for at least
one allergen in none of the patients in the COPD group, in all
(2/2) AS patients and in 67% (6/9) of the ANS patients.
However, those results were available for a minority of
patients in all three patient groups and differences between
AS and both other groups were not significant.
Treatment
At the level of the specialist, 77% of the COPD patients
received a fixed combination treatment (FCT) of LABA and
inhaled corticosteroids (ICS) compared to 87% of the AS
patients and 83% of the patients in the ANS group. ICS (ICS
only or ICS plus FCT) were prescribed in 2%, 20% and 21% of
the COPD, AS and ANS patients, respectively. Treatment
with LTRA was prescribed in 2% (1/47) of the patients in the
COPD group, 47% in the AS and 34% in the ANS. Tiotropium
was given to 74% of the COPD patients, compared to only 7%
(1/15) of the AS patients and none of the ANS patients.
The combination of ICS/LABA plus tiotropium was
prescribed in 60% of the COPD patients and in 7% (1/15) of
the AS patients. None of the ANS patients received thiscombination of drugs. The combination of ICS/LABA and
LTRA was given to 2% (1/47) of the COPD patients, to 40% of
the AS patients and to 31% of the ANS patients. None of the
COPD patients received ICS plus LTRA, but this combination
was found in 13% of the AS and in 7% of the ANS. However, it
should be noted that none of those results were statistically
significantly different.
In the GP population, 70% of the COPD patients were
treated with a fixed combination of LABA/ICS versus 87% and
72% in the AS and ANS group, respectively. Both in the
specialist and in the GP population this percentage was the
highest in the AS group. Treatment with ICS alone was
prescribed for 14%, 17% and 12% of the COPD, AS and ANS
patients, respectively. None of the COPD patients was
treated with LTRA in comparison to 17% and 30% of the
patients in the AS and ANS groups, respectively. Treatment
with tiotropium was prescribed to 62% of the COPD patients
and remarkably also to 30% (7/23) of the AS patients and to
10% (4/40) of the ANS patients. Almost half of the COPD
patients (46%) were treatedwith ICS/LABAþ tiotropium; 30%
(7/23) and 8% (3/40) of the AS andANS patients, respectively,
were treated with this combination. The combination of
ICSþ LTRA was given to 5% (2/40) of the ANS patients and to
none of the other patients. ICS/LABAþ LTRA combination
was the therapeutic scheme for none of the COPD patients,
17% of the AS patients and 22% of the ANS patients. None of
these data were statistically significantly different.
Discussion
At the level of the specialists, the characteristics of the
non-smoking asthma patients and the COPD patients
included in this study correspond with what would be
expected based on published data.13 In contrast to the
specialist patient population, the GP patient population
consisted mainly of asthma patients.
In both populations, COPDwasmainly diagnosed after the
age of 40, whereas most of the ANS were diagnosed at
a younger age. The link between tobacco consumption and
COPD was confirmed as about 94% of the COPD patients
presented a history of smoking. In the GP population, the
association with smokingwas not so strong in the COPD group
as only 78%of theCOPDpatientswere (ex-)smokers. In theGP
population, age at diagnosis was equally distributed over
both age groups for the (ex-)smoking asthma patients and in
general, diagnosis was made a bit later compared to what is
seen in the non-smoking asthmatic group. In both patient
(Ex-)smoking asthma patients and Belgian practice 1209populations, at the level of the patient characteristics, the
group of the (ex-) smoking asthma patients was closer to the
non-smoking asthma patients, but with some overlapping
featureswith theCOPDpatients. Therewasa shift to an older
age before asthma was diagnosed.
In the specialist population, atopic conditions remained
a common characteristic, and the association with cardio-
vascular comorbidity was clearly more present in the AS
group compared to the ANS group, but not as frequent as in
COPD patients. This increased prevalence of cardiovascular
disease might be the consequence of tobacco consump-
tion.14 Similarly,GPs reported atopic conditionsmostly in the
ANS, and less frequently in (ex)-smoking asthmapatients and
least in COPD patients. However, it is remarkable that 25% of
the COPD patients had a history of atopic conditions. The
question is if this was a real fact or if it suggests a diagnostic
problemeither of COPD, of atopic conditions, or even of both
of them. Since we only collected data on IgE Cap tests and
prick tests without a history of allergy, these tests tell us
something about sensitisation but not on allergy per se.
In the GP population, cardiovascular comorbidity was
highly prevalent in all three patient groups, especially in
the non-smoking patients. This could be explained by
a more holistic approach of the patients by the GP where
common problems like for example hypertension might also
be more frequently detected.
In the specialist as well as in the GP population, cough,
dyspnoea and wheezing were reported in a similar
percentage for non-smoking asthma patients. Cough and
especially dyspnoea were most predominant in COPD, while
wheezing was relatively less important. Cough outside
periods of exacerbations was dry in the majority of the non-
smoking asthma patients, whereas it had a productive char-
acter in COPD. In both the GP and specialist population,
smoking seemed to lead to an aggravation of asthma as
documented by the increased incidence of cough and dysp-
noea, the more frequent association of common cold with
bronchitis, and the higher incidence of hospitalizations for
respiratory problems. However, the type of cough was very
similar to that of the non-smoking asthma patient. In the GP
population, the atypical, very high values seen for bronchitis
with common cold in both asthma groups, and on the other
hand for night-time dyspnoea in COPD patients, raise the
hypothesis of a diagnostic problem.
In summary, we can conclude that patient characteristics
of (ex-)smoking asthma patients in general practice are
intermediary to and different from those seen both in non-
smoking asthma patients and in COPD patients. Additionally,
in this group of (ex-)smoking asthma patients, differences in
the age of patients could be observed for wheezing
(specialist population), dyspnoea, cold and hospitalization
(GP population). Regarding the results of the diagnostic
tests, smoking asthma patients showed more similarities
with non-smoking asthma patients than with COPD patients.
It should be noted that, in our population, 10% of the
COPD patients had a pre-bronchodilator Tiffeneau value
>70%. A possible explanation for this observation is that
patients with GOLD stage 0 were also considered to suffer
from COPD. On the other hand, a non negligible number of
asthmatic patients had a sustained obstruction after bron-
chodilation, especially in the AS group. Although the GOLD
classification is specific to COPD and not developed forasthma, we applied this classification also to both asthma
patient groups, in order to allow for a comparison of
pulmonary function impairment in all three patient groups.
Non-smoking asthma patients seemed to have a better
preserved lung function compared to the (ex-)smoking
asthma patients, who had on their turn better values than
the COPD patients. Reversibility both in absolute value as in
percentage of the predicted/baseline value was higher
in both asthma patient groups compared to what was seen
in the COPD group. An important observation is that less
than half of the asthma patients showed a reversibility
12%. Concerning the other tests, we notice that the
carbon monoxide diffusing capacity was diminished in 38%
of the AS patients. This could possibly be explained by the
interaction that smoking had on the results of this test.15e17
Attention should be paid to the relatively high number of
ambiguous diagnoses in all three patient groups. Especially
in the GP population, the small number of available
spirometry data in all three patient groups could raise
questions about the accuracy of the attributed diagnosis.
Data concerning peak expiratory flow rate were also very
rare in this population. One could ask on which clinical
arguments or on what diagnostic tests the GPs confirm their
diagnosis. This confirms the hypothesis that the distinction
between asthma and COPD is not always clear and that
there is an important overlap between those two diseases.
A bit more than 75% of the patients in the COPD group
were treated with a fixed combination of LABA/ICS.
However, only 52% of the COPD patients were in GOLD stage
III-IV. An important part of COPD patients were treated with
tiotropium and in 60% of the cases tiotropium was combined
with ICS/LABA. (Ex-)smoking asthma patients seemed to be
treated in a similar way as non-smoking patients, with
a majority of patients being treated with a fixed combina-
tion of LABA/ICS and also LTRA as a valid therapeutic
option. These were most often used in add-on therapy, and
more often in AS patients compared to ANS patients.
Regarding the management of the (ex-)smoking compared
to the non-smoking patients, there seemed to be no
uniformity at general practitioner’s level. Here also, most
patients in all three groups were treated with a combina-
tion of ICS/LABA. However, a considerable number of
asthma patients, especially in the smoking group, were
treated with tiotropium with or without ICS/fixed combi-
nation. A possible explanation for this atypical prescription
habits is again the absence of a correct diagnosis.
As already discussed, this study has several limitations:
the high number of ambiguous diagnoses in all patient
groups, the small number of available spirometry data in all
three patient groups, especially in the GP population, the
different population for specialists and GPs and the retro-
spective design of the study. Despite these limitations, we
believe that valuable data have been obtained regarding
the (ex)-smoking asthma patients. Prospective studies with
a larger number of patients in all groups are required to
confirm these data.Conclusion
As a whole, the AS were somewhere in between COPD
patients and ANS for a large number of the characteristics
1210 M. Decramer et al.studied, suggesting that they are an intermediate pheno-
type between COPD and asthma. These differences were
present in both the specialist and GP population.
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